Logo

BLFS

BioLife Solutions, Inc.

BLFS

BioLife Solutions, Inc. • NASDAQ
$26.50 ▼ -0.67% (-0.18)
Market Cap $1.28 B
52w High $29.62
52w Low $19.10
Dividend Yield 0%
P/E -69.74
Volume 240.54K
Outstanding Shares 48.14M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $28.067M ▲ $18.158M ▼ $621K ▲ 2.213% ▲ $0.01 ▲ $2.546M ▲
Q2-2025 $25.421M ▲ $33.076M ▲ $-15.838M ▼ -62.303% ▼ $-0.33 ▼ $-14.33M ▼
Q1-2025 $23.941M ▲ $17.004M ▲ $-448K ▼ -1.871% ▲ $-0.009 ▼ $166K ▼
Q4-2024 $-3.424M ▼ $-16.505M ▼ $12.459M ▲ -363.873% ▼ $0.27 ▲ $6.747M ▲
Q3-2024 $30.571M $23.365M $-1.703M -5.571% $-0.037 $853K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $78.954M ▼ $392.081M ▲ $38.342M ▼ $353.739M ▲
Q2-2025 $81.766M ▼ $387.24M ▼ $40.085M ▼ $347.155M ▼
Q1-2025 $88.58M ▼ $395.141M ▼ $42.517M ▼ $352.624M ▲
Q4-2024 $104.584M ▲ $399.487M ▲ $50.578M ▼ $348.909M ▲
Q3-2024 $34.188M $381.652M $56.191M $325.461M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $621K ▲ $6.104M ▼ $-5.967M ▲ $5.87M ▲ $0 ▲ $2.802M ▼
Q2-2025 $-15.838M ▼ $7.368M ▲ $-39.533M ▼ $-2.878M ▲ $-35.043M ▼ $5.625M ▲
Q1-2025 $-448K ▼ $1.727M ▲ $-27.176M ▼ $-2.992M ▲ $-28.441M ▼ $1.552M ▲
Q4-2024 $12.459M ▲ $1.645M ▼ $73.637M ▲ $-4.086M ▼ $71.225M ▲ $583K ▼
Q3-2024 $-15.276M $4.802M $-1.681M $-1.041M $2.116M $3.688M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $30.00M ▲$20.00M ▼$20.00M ▲$30.00M ▲
Rental Revenue
Rental Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown over the past few years but with some bumps along the way, reflecting both industry momentum and some volatility in demand. The company is clearly able to generate healthy gross profit on what it sells, but it has not yet translated that into consistent profits at the operating or net income level. Losses peaked a couple of years ago and have since narrowed, suggesting cost discipline and better focus after divestitures, yet the business still runs slightly in the red. Overall, the income statement tells a story of a high‑potential, still‑maturing company moving gradually toward breakeven but not firmly profitable yet.

Balance Sheet

Balance Sheet The balance sheet looks relatively solid for a small, innovation‑driven company. Total assets remain sizable, and the company keeps a meaningful cash cushion, though that balance has moved around over the years. Debt levels are modest compared with the equity base, indicating limited financial leverage and some room to maneuver in a downturn. Equity has held up well, implying that past losses have not yet overly eroded the company’s capital position. In simple terms, the financial foundation appears sound enough to support continued R&D and growth efforts, though not without the usual risks of a niche healthcare business.

Cash Flow

Cash Flow Cash generation has been close to breakeven for several years, with periods of modest cash burn followed by improvement. Recently, operating cash flow and free cash flow have turned slightly positive, which is an encouraging sign that the core business is becoming more self‑sustaining. Capital spending has been restrained, so the company is not overextending itself on big, long‑payback projects. Overall, the cash flow profile points to a business that is past the most cash‑hungry stage of its build‑out but still needs to prove that it can consistently fund growth and innovation from its own operations.

Competitive Edge

Competitive Edge BioLife sits in a strategically important niche: the tools and materials needed to preserve, store, and handle cell and gene therapies. Its preservation media and related tools are deeply embedded in many clinical trials and approved therapies, which creates high switching costs for customers once their processes are validated. The company complements this with a broad toolkit across the cell therapy workflow, strong regulatory support, and a meaningful patent portfolio. That combination gives it a defensible position. The flip side is concentration in a specialized market that is still evolving, so performance remains tied to the pace and success rate of cell and gene therapy development globally.

Innovation and R&D

Innovation and R&D Innovation is at the heart of the BioLife story. The company continues to refine its core preservation media while adding new technologies, such as ice recrystallization inhibitors, that aim to further improve cell viability. The new biopreservation excellence center underscores a commitment to being a scientific and training hub, not just a product vendor. Management has also pruned non‑core activities, sharpening focus on cell processing and high‑margin biopreservation solutions. The main risk is execution: turning promising technologies and facilities into widely adopted, profitable products in a fast‑moving, highly technical field.

Summary

BioLife combines an improving but still loss‑making financial profile with a strong strategic position in a high‑growth corner of healthcare. The income statement and cash flows suggest a business moving toward sustainability but not yet delivering stable profits. The balance sheet is relatively healthy, with modest debt and adequate cash, giving it some resilience. Competitively, the company benefits from high switching costs, embedded products, and a broad solutions offering that tie it closely to the growth of cell and gene therapies. Its future will likely hinge on continued successful innovation, broader adoption of its technologies, and disciplined cost management as the cell and gene therapy market matures. Uncertainty remains meaningful, but the company is clearly positioned at a critical chokepoint in an important emerging industry.

NEWS

November 20, 2025 · 8:04 AM UTC

BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence

Read more

November 17, 2025 · 7:15 AM UTC

BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025

Read more

November 6, 2025 · 4:03 PM UTC

BioLife Solutions Reports Third Quarter 2025 Financial Results

Read more

October 23, 2025 · 4:03 PM UTC

BioLife Solutions to Report Third Quarter 2025 Financial Results and Business Update on November 6, 2025

Read more

October 7, 2025 · 8:04 AM UTC

BioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary

Read more